Pham M, Rhinn H, Auzeil N, Regazzetti A, Harami D, Scherman D
Drug Metab Lett. 2011; 5(2):73-84.
PMID: 21457135
PMC: 3743746.
DOI: 10.2174/187231211795305221.
Young H
J Leukoc Biol. 2011; 89(3):327-8.
PMID: 21357247
PMC: 3040466.
DOI: 10.1189/jlb.1010580.
Brauer R, Wang L, Woon S, Bridewell D, Henare K, Malinger D
Neoplasia. 2010; 12(9):755-65.
PMID: 20824052
PMC: 2933696.
DOI: 10.1593/neo.10636.
Cheng G, Sun J, Fridlender Z, Wang L, Ching L, Albelda S
J Biol Chem. 2010; 285(14):10553-62.
PMID: 20118240
PMC: 2856263.
DOI: 10.1074/jbc.M109.065631.
Hinnen P, Eskens F
Br J Cancer. 2007; 96(8):1159-65.
PMID: 17375046
PMC: 2360146.
DOI: 10.1038/sj.bjc.6603694.
Comparative efficacy of DMP 840 against mouse and human solid tumor models.
Lorusso P, Demchik L, Dan M, Polin L, Gross J, Corbett T
Invest New Drugs. 1995; 13(3):195-203.
PMID: 8729946
DOI: 10.1007/BF00873800.
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies.
OReilly S, Rustin G, Farmer K, Burke M, Hill S, Denekamp J
Br J Cancer. 1993; 67(6):1342-5.
PMID: 8512818
PMC: 1968514.
DOI: 10.1038/bjc.1993.248.
The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma.
French R, Cummings J, MacLellan A, Macpherson J, Ritchie A, Smyth J
Cancer Chemother Pharmacol. 1993; 32(2):156-61.
PMID: 8485810
DOI: 10.1007/BF00685620.
Inhibition of antibacterial activity of himastatin, a new antitumor antibiotic from Streptomyces hygroscopicus, by fatty acid sodium salts.
Mamber S, Brookshire K, Dean B, FIRESTONE R, Leet J, Matson J
Antimicrob Agents Chemother. 1994; 38(11):2633-42.
PMID: 7872760
PMC: 188254.
DOI: 10.1128/AAC.38.11.2633.
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.
De Forni M, Chabot G, Armand J, Gouyette A, Recondo G
Cancer Chemother Pharmacol. 1995; 35(3):219-24.
PMID: 7805180
DOI: 10.1007/BF00686551.
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
Laws A, Matthew A, Double J, Bibby M
Br J Cancer. 1995; 71(6):1204-9.
PMID: 7779712
PMC: 2033820.
DOI: 10.1038/bjc.1995.234.
Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
ODwyer P, SHOEMAKER D, ZAHARKO D, Grieshaber C, Plowman J, Corbett T
Cancer Chemother Pharmacol. 1987; 19(1):6-10.
PMID: 3545524
DOI: 10.1007/BF00296246.
Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides.
Banning J, Abramson H, WORMSER H, Wu J, Corbett T
Cancer Chemother Pharmacol. 1987; 19(3):207-12.
PMID: 3472676
DOI: 10.1007/BF00252974.
Flavone acetic acid: a nonlinear pharmacokinetic model.
Gouyette A, Kerr D, Kaye S, Setanoians A, Cassidy J, Bradley C
Cancer Chemother Pharmacol. 1988; 22(2):114-9.
PMID: 3409441
DOI: 10.1007/BF00257307.
Dose-dependent pharmacokinetics of flavone acetic acid in mice.
Damia G, Zanette M, Rossi C, Mandelli R, Ferrari A, DIncalci M
Cancer Chemother Pharmacol. 1988; 22(1):47-50.
PMID: 3396145
DOI: 10.1007/BF00254180.
Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
Giavazzi R, Garofalo A, Damia G, Garattini S, DIncalci M
Br J Cancer. 1988; 57(3):277-80.
PMID: 3355765
PMC: 2246519.
DOI: 10.1038/bjc.1988.59.
Is the P388 murine tumor no longer adequate as a drug discovery model?.
Corbett T, Valeriote F, Baker L
Invest New Drugs. 1987; 5(1):3-20.
PMID: 3298130
DOI: 10.1007/BF00217664.
Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).
Bibby M, Double J, Loadman P
Br J Cancer. 1988; 58(3):341-4.
PMID: 3179187
PMC: 2246591.
DOI: 10.1038/bjc.1988.215.
Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).
Pratesi G, Manzotti C, Damia G, DIncalci M
Br J Cancer. 1988; 58(2):144-6.
PMID: 3166904
PMC: 2246749.
DOI: 10.1038/bjc.1988.181.
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
Kerr D, Maughan T, NEWLANDS E, Rustin G, Bleehen N, Lewis C
Br J Cancer. 1989; 60(1):104-6.
PMID: 2803908
PMC: 2247346.
DOI: 10.1038/bjc.1989.230.